Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
837
datasets available to search
ShareScore release 0.9.0
Dataset results
837 results for “endometrial cancer”
Sentinel Node Biopsy in Endometrial Cancer
ClinicalTrials.gov study NCT04073706. IPD Sharing: NO. Countries: 7. Publications: 1.
Sentinel Node Mapping in Women With Endometrial and Cervical Cancer
ClinicalTrials.gov study NCT02820506. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Weight Loss Management in Endometrial Cancer Survivors
ClinicalTrials.gov study NCT06877572. IPD Sharing: YES. Countries: 1. Publications: 18.
Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer
ClinicalTrials.gov study NCT00023894. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations
<p>Data set linked to the paper, "Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations". Pre-print of the paper is here: <a href="https://doi.org/10.1101/2020.06.16.146803">https://doi.org/10.1101/2020.06.16.146803</a>.</p> <p> </p> <p>cross_cancer_sum_stats.txt.gz contains summary genome-wide association statistics for susceptibility to single cancers (breast (BR), prostate (PR), ovarian (OV), endometrial (EN), estrogen receptor (ER)-positive breast (POS), ER-negative breast (NEG), and high-grade serous ovarian (HGS) cancers) and from the cross-cancer meta-analysis (main [main] and subtype-focused [sub]). EA in the header refers to the effect allele, OA is the other allele, EAF is the effect allele frequency in the largest of the single cancer data sets (BR), IMPR2 is the imputation quality in the largest of the single cancer data sets (BR), SE is the standard error, PVAL is the P-value, RE2Cs1 is the RE2C statistic mean effect part, RE2Cs2 is the RE2C statistic heterogeneity part, RE2Cp* is the RE2C* P-value. More on RE2Cp* can be found here: <a href="http://software.buhmhan.com/RE2C/index.php?mid=contact&act=dispBoardWrite">http://software.buhmhan.com/RE2C/index.php?mid=contact&act=dispBoardWrite</a> and in <a href="https://academic.oup.com/bioinformatics/article/33/14/i379/3953957">https://academic.oup.com/bioinformatics/article/33/14/i379/3953957</a> SNP names in cross_cancer_sum_stats.txt.gz include the chromosome and build 37 position.</p> <p> </p> <p>main_tetrachoric_corr_matrix.txt and subtype_tetrachoric_corr_matrix.txt provide the tetrachoric correlation matrices used in the main and subtype-focused meta-analyses. These were also used to specify the cryptic.cor argument of the exh.abf function of MetABF. More on MetABF can be found here: <a href="https://github.com/trochet/metabf">https://github.com/trochet/metabf</a> and in <a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/gepi.22202">https://onlinelibrary.wiley.com/doi/abs/10.1002/gepi.22202</a></p> <p> </p> <p>prior_sigmas_for_metabf.txt contains the values used to specify the prior.sigma argument of the exh.abf function in MetABF.</p> <p> </p> <p>The breast cancer data used are described in <a href="https://pubmed.ncbi.nlm.nih.gov/29059683/"><strong>PMID 29059683</strong></a> and can be downloaded from <a href="http://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/oncoarray-and-combined-summary-result/gwas- summary-results-breast-cancer-risk-2017/">http://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/oncoarray-and-combined-summary-result/gwas- summary-results-breast-cancer-risk-2017/</a> (this link also includes acknowledgements). The prostate cancer data are described in <a href="https://pubmed.ncbi.nlm.nih.gov/29892016/"><strong>PMID 29892016</strong></a> and can be downloaded from: <a href="http://practical.icr.ac.uk/blog/?page_id=8164">http://practical.icr.ac.uk/blog/?page_id=8164</a> (this link also includes acknowledgements). The ovarian cancer data used are described in <a href="https://pubmed.ncbi.nlm.nih.gov/28346442/"><strong>PMID 28346442</strong></a> and can be downloaded from <a href="https://www.ebi.ac.uk/gwas/studies/GCST004415">https://www.ebi.ac.uk/gwas/studies/GCST004415</a>. The endometrial cancer data are described in <a href="https://pubmed.ncbi.nlm.nih.gov/30093612/"><strong>PMID 30093612</strong></a> and can be downloaded from <a href="https://www.ebi.ac.uk/gwas/studies/GCST006464">https://www.ebi.ac.uk/gwas/studies/GCST006464</a>. These links point to the same data that form the basis of the cross_cancer_sum_stats.txt.gz file.</p> <p> </p> <p><strong>The sample size and precision of the data presented should preclude identification of any individual study participant. However, in downloading these data, you undertake not to attempt to identify individual study participant and not to re-post these data to a third-party website. Please cite the PMIDs highlighted above along with the appropriate acknowledements if you use the cross_cancer_sum_stats.txt.gz file.</strong></p> <p> </p> <p>If you have any questions about this repository, please email Siddhartha Kar at siddhartha dot kar at bristol dot ac dot uk</p>
Data from: Prognostic and clinical significance of miRNA-205 in endometrioid endometrial cancer
Endometrial cancer is one of the most common malignancies of the reproductive female tract, with endometrioid endometrial cancer being the most frequent type. Despite the relatively favourable prognosis in cases of endometrial cancer, there is a necessity to evaluate clinical and prognostic utility of new molecular markers. MiRNAs are small, non-coding RNA molecules that take part in RNA silencing and post-transcriptional regulation of gene expression. Altered expression of miRNAs may be associated with cancer initiation, progression and metastatic capabilities. MiRNA-205 seems to be one of the key regulators of gene expression in endometrial cancer. In this study, we investigated clinical and prognostic role of miRNA-205 in endometrioid endometrial cancer. After total RNA extraction from 100 archival formalin-fixed paraffin-embedded tissues, real-time quantitative RT-PCR was used to define miRNA-205 expression levels. The aim of the study was to evaluate miRNA-205 expression levels in regard to patients' clinical and histopathological features, such as: survival rate, recurrence rate, staging, myometrial invasion, grading and lymph nodes involvement. Higher levels of miRNA-205 expression were observed in tumours with less than half of myometrial invasion and non-advanced cancers. Kaplan-Maier analysis revealed that higher levels of miRNA-205 were associated with better overall survival (p = 0,034). These results indicate potential clinical utility of miRNA-205 as a prognostic marker.
MITO END-3: efficacy of Avelumab immunotherapy according to molecular profiling in first line endometrial cancer therapy
<p>Immunotherapy combined to chemotherapy significantly improves progression free survival compared to first line chemotherapy alone in advanced endometrial cancer, with a much larger effect size in microsatellite-instability high (MSI-H) cases. New biomarkers might help to select patients that may have benefit among those with a microsatellite-stable (MSS) tumor.</p> <p>Methods.</p> <p>In a pre-planned translational analysis of the MITO END-3 trial we assessed the significance of genomic abnormalities in patients randomized to standard carboplatin/paclitaxel without or with avelumab.</p> <p>Results.</p> <p>Out of 125 randomized patients, 109 had samples eligible for Next Generation Sequencing (NGS) analysis and 102 had MSI tested. According to The Cancer Genome Atlas (TCGA) there were 29 cases MSI-H, 26 MSS TP53 wild type (wt), 47 MSS TP53 mutated (mut), and one case with <em>POLE</em> mutation. Four mutated genes were present in more than 30 % of cases: <em>TP53</em>,<em> PIK3CA</em>,<em> ARID1A</em>,<em> PTEN</em>. Eleven patients (10 %) had a BRCA 1/2 mutation (5 in MSI-H and 6 in MSS). High TMB (≥ 10Muts/Mb) was observed in all MSI-H patients, in 4 out of 47 MSS/<em>TP53</em>mut, and in no case in the MSS/<em>TP53</em>wt category. The effect of avelumab on progression-free survival (PFS) significantly varied according to TCGA categories, being favorable in MSI-H and worst in MSS/TP53mut (P interaction=0.003); a similar non-significant trend was seen in survival analysis. <em>ARID1A</em> and <em>PTEN</em> also showed a statistically significant interaction with treatment effect, that was better in presence of the mutation (<em>ARID1A</em> P interaction=0.01; <em>PTEN</em> P interaction=0.002).</p> <p>Conclusion</p> <p>The MITO END-3 trial results suggest that <em>TP53 </em>mutation is associated with poor effect of avelumab, while mutations of <em>PTEN</em> and <em>ARID1A</em> are related to a positive effect of the drug in patients with advanced endometrial cancer.</p>
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
ClinicalTrials.gov study NCT01536392. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of Uterine Manipulator on Recurrence and Mortality of Endometrial Cancer
ClinicalTrials.gov study NCT02943811. IPD Sharing: NO. Countries: 0. Publications: 2.
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
ClinicalTrials.gov study NCT01289041. IPD Sharing: Not stated. Countries: 13. Publications: 0.
An Endometrial Cancer Chemoprevention Study of Metformin
ClinicalTrials.gov study NCT01697566. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
ClinicalTrials.gov study NCT01111461. IPD Sharing: Not stated. Countries: 8. Publications: 0.
FitEx for Endometrial Cancer Survivors: Initial Efficacy
ClinicalTrials.gov study NCT05737745. IPD Sharing: NO. Countries: 1. Publications: 0.
Photoacoustic Endoscopy in Endometrial Cancer
ClinicalTrials.gov study NCT01498237. IPD Sharing: Not stated. Countries: 0. Publications: 31.
Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion
ClinicalTrials.gov study NCT01979003. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
ClinicalTrials.gov study NCT00723255. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
ClinicalTrials.gov study NCT05542407. IPD Sharing: NO. Countries: 1. Publications: 0.
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
ClinicalTrials.gov study NCT03485729. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
ClinicalTrials.gov study NCT05524389. IPD Sharing: Not stated. Countries: 0. Publications: 1.
The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
ClinicalTrials.gov study NCT00910091. IPD Sharing: Not stated. Countries: 12. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.